CSL889 Haemopexin CRF
Sponsor
Sponsor Name Pending
Description
Non-Transfusion Sickle Cell Disease: CSL889 haemopexin CRF - Safety and tolerability of CSL889 in Sickle Cell Disease: A Phase 1, Multi-Centre, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients with Stable Sickle Cell Disease.
Site name
UCLH
Site PI
Site PI Pending
Start date
Start Date Pending
End date
End Date Pending
